Sillajen’s co-development agreement of renal cancer treatment with U.S. RegeneronPharmaceuticals

Sillajen(CEO Eun-Sang Moon) announced in a joint statement on the 8^th that it signed a co-research agreement of renal cell carcinoma(renal cancer) treatment development with U.S. ‘RegeneronPharmaceuticals.’

Under the agreement, the two companies are planning to conduct a Phase 1b clinical trial to confirm safety and efficacy of the combination therapy of Sillajen’s ‘Pexa-Vec’ and Regeneron’s ‘...